DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

RMD·ResMed Inc.

$.
-. (-.%)
After Hours
High
$211.56
Open
$209.07
Market Cap
30.17B
52W High
$293.81
Low
$206.06
P. Close
$206.12
P/E
19.85
52W Low
$198.61
Fwd P/E
17.05
Mean Target
$270.60
Technical Score (1D)
18
SELL
News Sentiment
53
MIXED
Argus Research has initiated coverage on ResMed with a 'Hold' rating, presenting a balanced view of the company's prospects. This initiation comes as ResMed maintains a strong market position in sleep apnea devices and explores growth in adjacent markets. However, potential headwinds such as competitive pressures and evolving reimbursement landscapes are noted. Investors should closely monitor ResMed's innovation pipeline and its strategies for expanding its product offerings.
Earnings Summary
ResMed Inc. is a global medical technology company focused on developing and distributing devices and software for respiratory health, particularly sleep apnea and other breathing disorders. Operating within the Healthcare sector's Medical Instruments & Supplies industry, ResMed offers a comprehensive suite of diagnostic tools, cloud-based patient monitoring platforms, and patient engagement software, aiming to improve outcomes and streamline care in the respiratory market. In its most recent reported quarters, ResMed demonstrated a pattern of exceeding analyst expectations. For Q2 2025, the company reported EPS of $2.55 against an estimate of $2.48, with revenue at $1.35 billion. This followed Q1 2025 where EPS was $2.37 versus an estimate of $2.36, and revenue was $1.29 billion. Prior to this, Q4 2024 saw actual EPS of $2.43 against an estimate of $2.31, with revenue at $1.28 billion. This performance indicates a consistent trend of delivering results at or above consensus, with revenue generally showing an upward trajectory across these periods. Looking at the historical streak, ResMed has shown a positive year-over-year growth trajectory in its reported earnings and revenue. The company has a notable pattern of beating analyst estimates for earnings per share in recent quarters, with Q3 2026 being a recent example where actual EPS of $2.86 surpassed the estimate of $2.79, alongside a revenue beat of $1.43 billion against an estimate of $1.42 billion. This consistent performance suggests a reliable operational execution and market demand for its products. Recent news highlights a strengthening investment narrative for ResMed, driven by robust growth in the sleep apnea market and an improved profit outlook, with projections indicating significant market growth through 2034. The company is noted as a key player in both therapeutic and diagnostic segments, suggesting continued demand for its solutions. Investors will be watching for the sustainability of this demand, commentary on global mask portfolio performance, and any forward-looking guidance that may impact future financial results, particularly in light of the strong growth outlook for the sleep apnea device market.

EPS

EstBeatMiss
$2.23$2.41$2.59$2.76$2.94Q4'24Q1'25Q2'25Q3'25Q3'26
QtrEstActual+/−
Q3'26$2.80$2.86+2.2%
Q3'25$2.50$2.55+2.1%
Q2'25$2.48$2.55+2.8%
Q1'25$2.36$2.37+0.4%
Q4'24$2.31$2.43+5.0%

Revenue

EstBeatMiss
$1.3B$1.3B$1.4B$1.4B$1.5BQ4'24Q1'25Q2'25Q3'25Q3'26
QtrEstActual+/−
Q3'26$1.4B$1.4B+0.6%
Q3'25 - $1.3B -
Q2'25 - $1.3B -
Q1'25 - $1.3B -
Q4'24 - $1.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RMD Stock Snapshot

RMD is currently trading at $206.10, giving ResMed Inc. a market cap of 30.17B and a P/E ratio of 19.9. Today's range spans $206.06–$211.56, with shares opening at $209.07 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 53/100.

Over the past year RMD has traded between $198.61 and $293.81 - the current price is +3.8% off the 52-week low and -29.9% from the high. 27 analysts cover the stock with a Buy consensus and a mean 12-month target of $270.60 (range $180.00–$340.00), implying upside of +31.3%.

Short sellers have a clear thesis in RMD - large-cap, Healthcare, 30.17B market cap. Score: 18/100 (SELL). Sentiment: neutral (53/100). Price: $206.10 (near 52-week lows). The current P/E ratio stands at 19.9. At this capitalization tier, the borrow is relatively easy, the liquidity absorbs the size, and the technical confirmation provides a clean stop-out level. The 52-week range of $198.61–$293.81 establishes the structural target zones - and the SELL signal is the systematic entry trigger.

Analyst coverage for RMD becomes a double-edged factor in a SELL phase: at 30.17B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 18/100 technical reading and neutral sentiment (53/100) at $206.10 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $198.61–$293.81 range establishes where that repricing lands.